Youâre reading a free article with opinions that may differ from The Motley Foolâs Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.
RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partnerâs brokerage products, these are focused on the trading of readily releasable securities.
Owain Bennallack and his fellow Fools Nathan Parmelee and Nate Weisshaar explore the mega-merger mania that has gripped the pharmaceutical sector. Do these big deals make sense for shareholders, and what should you be doing? They also bash bankers’ outrageous bonuses and weigh up the pros and cons of AIM shares, before concluding as usual with three shares worth watching.â
Are you looking to profit from this uncertain economy? â10 Steps To Making A Million In The Marketâ is the Motley Fool’s FREE guide to help Britain invest — better. We urge you to read the report today while it remains available. Just click here now!
